Molecular Theranostic Agent with Programmed Activation for Hypoxic Tumors

Seyoung Koo, Kondapa Naidu Bobba, Mi Young Cho, Hye Sun Park, Miae Won, Nithya Velusamy, Kwan Soo Hong, Sankarprasad Bhuniya, Jong Seung Kim

Research output: Contribution to journalArticle

Abstract

A theranostic, small-molecule-based prodrug, designed to be activated programmatically against hypoxic tumors, was successfully developed. The prodrug was stimulated to release the active chemotherapeutic drug in concurrent with a rhodol fluorophore in artificial hypoxia mimic conditions or an in vitro hypoxic environment. The extent of prodrug activation was monitored under the hypoxia condition by monitoring a fluorescence signal at 543 nm. The excellent therapeutic response and selective fluorescence labeling of biotin receptor overexpressed cancer cells ensured that the prodrug could be an effective strategy for the therapy of chronic hypoxic tumors.

Original languageEnglish
Pages (from-to)4648-4655
Number of pages8
JournalACS Applied Bio Materials
Volume2
Issue number10
DOIs
Publication statusPublished - 2019 Oct 21

Keywords

  • antitumor
  • drug targeting
  • hypoxia
  • prodrug
  • theranostic

ASJC Scopus subject areas

  • Biomaterials
  • Chemistry(all)
  • Biomedical Engineering
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Molecular Theranostic Agent with Programmed Activation for Hypoxic Tumors'. Together they form a unique fingerprint.

  • Cite this

    Koo, S., Bobba, K. N., Cho, M. Y., Park, H. S., Won, M., Velusamy, N., Hong, K. S., Bhuniya, S., & Kim, J. S. (2019). Molecular Theranostic Agent with Programmed Activation for Hypoxic Tumors. ACS Applied Bio Materials, 2(10), 4648-4655. https://doi.org/10.1021/acsabm.9b00722